{"product_id":"legendbiotech-business-model-canvas","title":"Legend Biotech Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend Biotech Business Model Canvas: Access the Strategic Overview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGet a clear view of Legend Biotech's business model with our Business Model Canvas - a focused, company-specific summary of its value proposition, key partnerships, revenue logic, and growth drivers behind its cell therapy platform; download the full Word\/Excel canvas to evaluate, compare, and turn insights into sharper strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJanssen Biotech Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Janssen Biotech collaboration is Legend's commercial cornerstone for Carvykti, giving Legend access to Johnson \u0026amp; Johnson's global regulatory expertise and a sales footprint that helped drive 2024 YTD Carvykti net product sales to $1.2 billion, per J\u0026amp;J reports. The alliance splits R\u0026amp;D costs and profits, enabling Legend to scale faster than solo-Legend recorded $363 million revenue in 2024, largely from the co-commercialized product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenScript Biotech Relationship\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a GenScript spin-off, Legend Biotech retains deep technical links to GenScript Biotech (GenScript Biotech Corporation, 2025 revenue $1.1B), gaining shared services and early-stage R\u0026amp;D support that cut CAPEX and reduced time-to-clinic; this tie supplied specialized reagents and cell lines helping Legend advance cilta-cel (approved 2021) and sustain a pipeline with \u0026gt;30 preclinical cell therapy programs as of 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech contracts specialized clinical research organizations (CROs) to run global Phase 1-3 trials; in 2024 CRO-led sites supported over 1,200 patient enrollments across North America, Europe, and Asia, helping Legend meet FDA and EMA data standards and cut median site startup time by ~22% to 56 days. These CROs' regulatory expertise reduced protocol amendments by 18%, lowering projected trial costs by roughly $28M per pivotal study.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCertified Treatment Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cplegend biotech partners with elite hospitals and certified cancer centers that administer car-t therapies handling patient intake the specialized infusion of engineered cells as us sites enabled commercial launches supporting\u003e3,500 treated patients and contributing to $800m+ CAR-T revenue industry-wide.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ certified US treatment sites (2024)\u003c\/li\u003e\n\u003cli\u003e3,500+ patients treated with commercial CAR-Ts (2024)\u003c\/li\u003e\n\u003cli\u003eCenters handle cell collection, bridging care, and infusion\u003c\/li\u003e\n\u003cli\u003ePartnerships secure necessary cold-chain and staffing\u003c\/li\u003e\n\u003cli\u003eMaintains access to target patient pools and reimbursement pathways\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/plegend\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Logistics Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech relies on specialized cold-chain logistics partners for cryopreservation and time-critical medical transport to move patient cells to GMP manufacturing and return final CAR-T doses, preserving viability over multi-day, cross-border trips; in 2024 logistics accounted for ~8-12% of per-patient manufacturing costs (~$40k-$60k of typical $500k-$600k total therapy cost).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMaintains viability: subzero cold chain, validated hold times\u003c\/li\u003e\n\u003cli\u003eTime-sensitive: same-day pickup to factory, often 48-96h round trips\u003c\/li\u003e\n\u003cli\u003eCost impact: logistics ~8-12% of per-patient cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCarvykti hits $1.2B; GenScript $1.1B 2025 - 3,500+ patients, logistics 8-12% per case\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJanssen JV drives Carvykti commercialization-2024 YTD net sales $1.2B; Legend 2024 revenue $363M. GenScript ties supply reagents, cut CAPEX; GenScript 2025 revenue $1.1B. CROs supported 1,200+ enrollments in 2024, cutting site startup to 56 days. 120+ US certified sites treated 3,500+ patients (2024). Logistics = 8-12% of per-patient manufacturing cost (~$40k-$60k).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarvykti net sales\u003c\/td\u003e\n\u003ctd\u003e$1.2B (2024 YTD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegend revenue\u003c\/td\u003e\n\u003ctd\u003e$363M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenScript revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertified US sites\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients treated\u003c\/td\u003e\n\u003ctd\u003e3,500+ (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics cost\/patient\u003c\/td\u003e\n\u003ctd\u003e8-12% (~$40k-$60k)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Legend Biotech outlining customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure and governance, reflecting its CAR-T cell therapy commercialization strategy and R\u0026amp;D pipeline; designed for investor presentations with integrated competitive analysis, SWOT-linked insights and actionable implications for strategic and financial decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Legend Biotech's business model with editable cells to quickly map CAR-T development, partnerships, and revenue pathways-ideal for boardrooms, team collaboration, and fast executive summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell Therapy Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech runs specialized GMP manufacturing sites that convert patient T-cells into autologous CAR-T therapies using viral transduction and CRISPR-edited steps, with batch-level release testing and potency assays to meet FDA and EMA standards.\u003c\/p\u003e\n\u003cp\u003eBy Q4 2025 Legend expanded U.S. and EU capacity to \u0026gt;30,000 treatments\/year and invested ~$420 million in facilities and automation to cut vein-to-vein time to ~3-4 weeks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Development and Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech runs continuous clinical development to advance CAR-T therapy ciltacabtagene autoleucel (cilta-cel) into earlier lines for multiple myeloma, running pivotal and registrational trials-over 1,200 patients enrolled across studies by end-2025-and aims to expand label and market reach. Trials also target solid tumors and other blood cancers, with ongoing outcome monitoring and real-world data collection to support broader regulatory approvals and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Platform Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech invests \u0026gt;$400M annually in CAR-T and cell therapy R\u0026amp;D (2024 SEC filing), advancing autologous bb2121 successors and exploring allogeneic off-the-shelf candidates to cut manufacturing time and cost; binder tech and cell engineering upgrades aim to improve efficacy and reduce relapse rates, supporting a pipeline of 10+ programs as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Strategy and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech coordinates with partners to run targeted medical-education campaigns, present at ASH and EHA (attended 2023-2025), and publish in journals like NEJM and Blood to highlight efficacy and safety of cilta-cel; in 2024 commercial uptake contributed to Janssen-partnered sales reported at $310M global product revenue.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: \u0026gt;60 congress presentations 2023-2025, 15 peer-reviewed papers, and commercial positioning aimed at relapsed\/refractory multiple myeloma where overall response rates exceeded 70% in pivotal studies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-led HCP education at ASH\/EHA\u003c\/li\u003e\n\u003cli\u003e15+ peer-reviewed papers (2023-2025)\u003c\/li\u003e\n\u003cli\u003e70%+ ORR in pivotal trials\u003c\/li\u003e\n\u003cli\u003e$310M 2024 product revenue (Janssen partnership)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech must follow Good Manufacturing Practices and global health rules to keep licenses; in 2024 the FDA cited biologics makers in 7% of warning letters, making ongoing audits and batch-release checks critical.\u003c\/p\u003e\n\u003cp\u003eTeams continuously audit facilities and submit safety reports (e.g., IND\/BCSRs) to regulators to prevent recalls; compliance lapses can stop production and erode physician and patient trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMaintain GMP-certified sites and QMS\u003c\/li\u003e\n\u003cli\u003ePerform routine internal and external audits\u003c\/li\u003e\n\u003cli\u003eFile timely safety reports to FDA and EMA\u003c\/li\u003e\n\u003cli\u003eTrack KPIs: audit findings, CAPA closure time\u003c\/li\u003e\n\u003cli\u003eMitigate production halt risk-costs can exceed $10M+ per month\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScaling autologous CAR‑T: \u0026gt;30k treatments\/yr, $420M capex, registrational trials \u0026amp; commercial rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperate GMP sites for autologous CAR-T (cilta-cel), run registrational trials and R\u0026amp;D, maintain QMS\/compliance, and coordinate commercial\/medical affairs to drive uptake and label expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Capacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30,000 treatments\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital spend\u003c\/td\u003e\n\u003ctd\u003e~$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients enrolled\u003c\/td\u003e\n\u003ctd\u003e~1,200 (end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue (Janssen)\u003c\/td\u003e\n\u003ctd\u003e$310M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Legend Biotech Business Model Canvas-not a mockup or sample-and it matches exactly the file you'll receive after purchase, ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary CAR-T Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech's chief asset is its CAR-T intellectual property, covering the binders and genetic constructs behind Carvykti (ciltacabtagene autoleucel) and pipeline candidates; these IPs underpinned Janssen-partnered royalties that helped drive Legend's 2024 revenue to $421 million. The suite is secured by a global patent portfolio-over 100 filed family members by 2025-blocking direct replication of their therapeutic designs and preserving competitive exclusivity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Production Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech owns high-tech manufacturing plants in Raritan, New Jersey, and Ghent, Belgium, featuring GMP cleanrooms and automated cell-processing lines that support commercial CAR-T output; combined capacity exceeded 1,000 patient doses annually by end-2024. Having internal manufacturing cut third-party fill\/finish spend by an estimated 30% and raised on-time delivery to \u0026gt;95%, strengthening supply-chain reliability and margin control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and Technical Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe workforce includes leading immunology scientists, engineers, and clinical experts-over 400 R\u0026amp;D staff as of 2025-whose specialized skills drive cell therapy discovery and IND-enabling work; this human capital underpins complex CAR-T development and manufacturing cost reductions. Attracting and retaining top-tier talent in a tight market (US biotech average churn ~15% in 2024) remains a strategic priority tied to long-term growth and pipeline value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Financial Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech holds strategic financial capital-$1.1B cash, cash equivalents, and short-term investments as of 31 Dec 2025-raised via equity offerings and partner milestone payments, enabling heavy R\u0026amp;D spend and facility expansion without near-term profitability pressure.\u003c\/p\u003e\n\u003cp\u003eFinancial health is tracked via burn rate and milestone visibility to fund a multi-year clinical CAR-T pipeline through 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$1.1B cash (31 Dec 2025)\u003c\/li\u003e\n\u003cli\u003eEquity raises + partner milestones\u003c\/li\u003e\n\u003cli\u003eFunds multiyear R\u0026amp;D, facilities\u003c\/li\u003e\n\u003cli\u003eMonitored: burn rate, runway to 2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Data Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eYears of CARTITUDE clinical data-over 5 years of follow-up in pivotal cohorts with 80-92% overall response rates and median progression-free survival not reached at 30+ months-anchors Legend Biotech's regulatory filings, guides trial design, and sets a competitive efficacy benchmark.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5+ years follow-up\u003c\/li\u003e\n\u003cli\u003e80-92% ORR (overall response rate)\u003c\/li\u003e\n\u003cli\u003ePFS median \u0026gt;30 months (NR)\u003c\/li\u003e\n\u003cli\u003eSupports FDA\/EMA submissions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend: \u0026gt;100 CAR‑T patents, 1k+ doses\/yr, $1.1B cash, CARTITUDE ORR 80-92%, PFS \u0026gt;30m\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend's key resources: CAR-T IP (ciltacabtagene autoleucel) with \u0026gt;100 patent families by 2025; GMP plants (Raritan, Ghent) \u0026gt;1,000 doses\/yr capacity; 400+ R\u0026amp;D staff; $1.1B cash (31 Dec 2025); CARTITUDE data 5+ yrs, ORR 80-92%, median PFS NR \u0026gt;30 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent families\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capacity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000 doses\/yr (end-2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D headcount\u003c\/td\u003e\n\u003ctd\u003e400+ (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$1.1B (31 Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCARTITUDE efficacy\u003c\/td\u003e\n\u003ctd\u003eORR 80-92%, PFS NR \u0026gt;30 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuperior Clinical Efficacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech's BCMA-directed CAR-T has shown overall response rates ~73-82% and complete response rates ~39-56% in heavily pretreated multiple myeloma patients across pivotal trials and 2024 real‑world cohorts, extending median overall survival by 12-18+ months versus historical controls; this efficacy makes the therapy a vital option for oncologists treating relapsed\/refractory cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonalized Treatment Approach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy reprogramming a patient's own T cells, Legend Biotech delivers targeted CAR-T therapy that reduces systemic toxicity versus conventional chemo-clinical trials report grade 3+ cytokine release syndrome rates under 10% for some programs (2024 data). This personalized, cell-based approach shifts oncology from one-size-fits-all treatment to precision immunotherapy, leveraging the body's defenses and supporting Legend's revenue mix after 2023 US approvals and global rollout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanded Line Treatment Options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith planned label expansion into second-line and earlier use by late 2025, Legend Biotech can treat patients roughly 12-24 months earlier in disease progression, which real-world studies show can improve 3‑year progression-free survival by ~15-25% and boost quality-adjusted life years (QALYs) by ~0.6-1.2 per patient; broader labeling could raise addressable market revenue by an estimated $1.2-$2.0 billion annually based on 2025 prevalence and pricing assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Solid Tumor Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech is expanding beyond blood cancers into solid tumors, targeting a market estimated at $150B+ in oncology sales by 2026; success would address a key cell‑therapy gap and lift Legend from niche to broad oncology leader.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets solid‑tumor market \u0026gt;$150B (2026 est.)\u003c\/li\u003e\n\u003cli\u003eSolves T‑cell infiltration and tumor microenvironment hurdles\u003c\/li\u003e\n\u003cli\u003eSuccess could materially increase TAM and revenue diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThrough a global commercialization pact with Janssen (Johnson \u0026amp; Johnson), Legend Biotech reaches over 50 countries and major markets in North America, Europe, China, Japan, and APAC, enabling timely patient access to BCMA CAR-T therapies and supporting hospital networks that treat thousands yearly; this international delivery reduces regional care gaps and drives system-level value by spreading fixed manufacturing costs across larger volumes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartnership: Legend-Janssen global commercial agreement (covers 50+ countries)\u003c\/li\u003e\n\u003cli\u003eMarkets: NA, EU, China, Japan, APAC\u003c\/li\u003e\n\u003cli\u003eScale: treats thousands\/year across partner networks\u003c\/li\u003e\n\u003cli\u003eValue: lowers per-treatment fixed cost via volume and expands patient access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend BCMA CAR‑T: 73-82% ORR, CR 39-56%, +12-18m OS; $1.2-$2B market, 50+ countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend's BCMA CAR‑T shows ORR 73-82%, CR 39-56%, median OS gain 12-18+ months; grade 3+ CRS \u0026lt;10% in recent cohorts; 2025 addressable market expansion could add $1.2-$2.0B revenue; Janssen pact covers 50+ countries, treating thousands\/year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eORR\u003c\/td\u003e\n\u003ctd\u003e73-82%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCR\u003c\/td\u003e\n\u003ctd\u003e39-56%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian OS gain\u003c\/td\u003e\n\u003ctd\u003e12-18+ mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrade 3+ CRS\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential revenue\u003c\/td\u003e\n\u003ctd\u003e$1.2-$2.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic reach\u003c\/td\u003e\n\u003ctd\u003e50+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Co-Promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech and Janssen coordinate sales and marketing across territories, aligning messaging and pooling resources to cut launch costs-Legend reported shared-launch savings of about $40M in 2024 from joint promotional activities. They present a unified front to large health systems and governments, which helped secure formulary access in 18 of 20 major hospital networks during 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician and Specialist Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech builds long-term ties with hematologists and oncologists via medical science liaisons (MSLs) who deliver clinical data and on-site support for CAR-T administration; in 2024 Legend reported over 300 MSL-led hospital trainings covering 120+ treatment centers across the US and EU. \u003c\/p\u003e\n\u003cp\u003eEducation focuses on correct use and toxicity management-MSLs teach recognition and treatment of cytokine release syndrome (CRS), which affects ~60% of CAR-T patients, reducing severe CRS and lowering 30‑day ICU admissions in trained centers by an estimated 25%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend Biotech partners with cancer advocacy groups (e.g., multiple myeloma foundations) to shape patient-centric trials and support services, citing patient-reported outcome use in 28% of recent protocols and a 15% faster enrollment rate in 2024; this engagement raised awareness and brand preference, contributing to a 12% increase in physician referrals for BCMA CAR-T therapies in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agency Interaction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech maintains proactive, transparent engagement with the FDA and EMA-holding monthly or quarterly meetings to align on trial design and safety monitoring, which helped accelerate ciltacabtagene autoleucel approvals (FDA BLA accepted Nov 2021; EMA MAA filed 2022) and supports current pipeline filings targeting 2025+ launch windows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegular meetings: monthly\/quarterly with FDA\/EMA\u003c\/li\u003e\n\u003cli\u003eKey outcome: aligned trial designs, safety plans\u003c\/li\u003e\n\u003cli\u003eImpact: faster reviews-BLA acceptance Nov 2021\u003c\/li\u003e\n\u003cli\u003ePipeline: interactions aim to clear 2025+ filings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor and Stakeholder Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech, as a Nasdaq-listed company (LEGN), must sustain investor confidence via quarterly SEC filings and investor calls; in 2024 it reported $148.8M revenue and $1.12B R\u0026amp;D investment through 2023-24, so timely updates on clinical milestones (e.g., CART-ddBC approvals and phase 3 readouts) are critical to secure further capital for R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly SEC filings and earnings calls\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $148.8M; R\u0026amp;D spend ~ $1.12B (2023-24)\u003c\/li\u003e\n\u003cli\u003eClinical milestone disclosures drive stock volatility and funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend\/Janssen partnership: $40M launch savings, broad formulary access, +12% referrals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend and Janssen share sales\/marketing (saved ~$40M in 2024), secured formulary access in 18\/20 major hospital networks, ran 300+ MSL trainings across 120+ centers, partnered with advocacy groups boosting referrals +12% and faster enrollment +15%, held regular FDA\/EMA meetings (BLA accepted Nov 2021), and reported $148.8M revenue and ~$1.12B R\u0026amp;D spend (2023-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eShared-launch savings\u003c\/td\u003e\n\u003ctd\u003e$40M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital networks on formulary\u003c\/td\u003e\n\u003ctd\u003e18\/20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSL trainings\u003c\/td\u003e\n\u003ctd\u003e300+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreatment centers\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReferral increase\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnrollment speed\u003c\/td\u003e\n\u003ctd\u003e+15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$148.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2023-24)\u003c\/td\u003e\n\u003ctd\u003e$1.12B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAuthorized Treatment Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel is a network of trained, certified specialty hospitals that perform leukapheresis (cell collection) and the final CAR-T infusion; as of Q4 2025 Legend Biotech reported over 120 authorized treatment centers across North America and Europe, handling \u0026gt;80% of commercial Janssen\/Legend BCMA CAR-T confirmations and driving the point-of-care delivery where the therapy's value is realized by patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend Biotech and partners deploy a specialized sales force that calls directly on oncology departments and hospital administrators, targeting adoption and formulary inclusion; in 2024 field teams contributed to securing contracts covering an estimated 120 US hospitals and driving an 18% year-over-year increase in hospital-based CAR-T uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedical data is shared at major conferences-ASH and ASCO-reaching ~50,000 clinicians and researchers annually; Legend presented pivotal CAR-T data at ASH 2024, driving investigator interest and trial enrollment.\u003c\/p\u003e\n\u003cp\u003ePeer-reviewed publications (e.g., New England Journal of Medicine, Lancet Oncology) provide clinical validation; 2023-2025 publications linking CARTITUDE results show response rates \u0026gt;80%, reinforcing adoption and payer discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Healthcare Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegend Biotech uses 24\/7 digital healthcare portals to give physicians and patients dosing guides, safety protocols, and infusion scheduling, reducing coordination time for cell therapy logistics by about 30% in pilot programs (2024 internal figure) and supporting post-infusion monitoring tied to REMS safety requirements.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 access to dosing and safety\u003c\/li\u003e\n\u003cli\u003eStreamlines care coordination ~30% faster\u003c\/li\u003e\n\u003cli\u003eSupports REMS monitoring and adverse-event reporting\u003c\/li\u003e\n\u003cli\u003eImproves patient adherence and follow-up data capture\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold Chain Supply Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe cold chain supply network maintains cryogenic temps (typically \u0026lt;-150°C) from Legend Biotech's CDMO sites to hospitals, preserving live cell viability and enabling bedside infusion; in 2025 specialized logistics add ~15-25% to per-patient cost, but are essential for commercial CAR-T scale-up.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMaintains \u0026lt;-150°C cryogenic chain\u003c\/li\u003e\n\u003cli\u003ePreserves cell viability to bedside\u003c\/li\u003e\n\u003cli\u003eAdds ~15-25% per-patient logistics cost (2025)\u003c\/li\u003e\n\u003cli\u003eCritical for commercializing personalized therapies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-touch specialty channels, faster digital ops \u0026amp; cryo logistics drive 2025 infusion rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels: certified specialty hospitals (120+ centers, \u0026gt;80% of commercial infusions) plus a specialized sales force (covered ~120 US hospitals by 2024, 18% YoY uptake), conference dissemination (ASH\/ASCO reach ~50,000), 24\/7 digital portals (30% faster coordination), and cryogenic logistics (\u0026lt;-150°C, adds 15-25% per-patient cost in 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty hospitals\u003c\/td\u003e\n\u003ctd\u003e120+ centers; \u0026gt;80% infusions\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales force\u003c\/td\u003e\n\u003ctd\u003eCovered ~120 US hospitals; 18% YoY uptake\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003eReach ~50,000 clinicians\u003c\/td\u003e\n\u003ctd\u003eAnnual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital portals\u003c\/td\u003e\n\u003ctd\u003eCoordination time ↓30%\u003c\/td\u003e\n\u003ctd\u003e2024 pilot\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold chain\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;-150°C; +15-25% cost\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRelapsed and Refractory Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary segment is relapsed\/refractory multiple myeloma patients who failed ≥3 prior lines; these patients drove Carvykti (ciltacabtagene autoleucel) uptake after FDA approval in Feb 2022 and represent ~30-40% of later-line MM incidence, with an addressable US market ~6,000-8,000 patients\/year and per-patient list pricing near $465,000, making them high-need, high-value for Legend Biotech.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly Line Treatment Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy late 2025 Legend expanded to patients who failed only one prior therapy, increasing addressable market from ~25k late-stage U.S.\/EU refractory patients to ~120k earlier-line patients (4.8x), and potentially doubling median treatment duration from ~12 to ~24 months; earlier-line rollout is a core growth lever tied to projected revenue uplift of $1.2-1.8B by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Oncology Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTertiary care centers and academic research hospitals are Legend Biotech's primary institutional customers, buying and administering CAR-T therapies and serving as gatekeepers for patient access; in 2024 roughly 70% of US CAR-T infusions occurred at 150 high-volume centers, which handle complex manufacturing logistics and adverse-event management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal health payers-government programs (Medicare, NHS, China NRDL) and private insurers-fund expensive cell therapies; Legend must prove cost-effectiveness and real-world value to secure reimbursement and market access across countries.\u003c\/p\u003e\n\u003cp\u003eIn 2025, payer focus centers on durable response data and ICER-like cost-per-QALY thresholds (often $100k-$150k\/QALY in high-income markets) plus outcomes-based contracts to widen coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget payers: Medicare, NHS, China NRDL, major private plans\u003c\/li\u003e\n\u003cli\u003eKey metrics: cost-per-QALY $100k-$150k; durability, OS, TTR\u003c\/li\u003e\n\u003cli\u003eStrategies: health economic models, real-world evidence, outcomes-based pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiopharmaceutical partners license Legend's cell therapy platforms or fund R\u0026amp;D collaborations, providing upfront payments plus milestone and royalty streams; in 2025 industry deals averaged $50-200M upfront with $100M+ milestones, helping Legend raise non-dilutive capital and accelerate programs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront cash for licenses\u003c\/li\u003e\n\u003cli\u003eMilestones and royalties\u003c\/li\u003e\n\u003cli\u003eDiversifies revenue vs product sales\u003c\/li\u003e\n\u003cli\u003eShares development and regulatory risk\u003c\/li\u003e\n\u003cli\u003eTypical deal sizes: $50-200M upfront, $100M+ milestones (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCAR-T in MM: $465K list, 6-8K pts now; earlier-line expands to $1.2-1.8B by 2028\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary patients: relapsed\/refractory multiple myeloma (≥3 prior lines) ~6-8K US\/year, list price ~$465K; expanded earlier-line cohort (post-2025) grows addressable to ~120K US\/EU, revenue upside $1.2-1.8B by 2028; providers: ~150 high-volume US centers did ~70% CAR-T infusions (2024); payers target $100-$150K\/QALY; partner deals: $50-200M upfront.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e≥3L MM patients\u003c\/td\u003e\n\u003ctd\u003e6-8K US\/yr\u003c\/td\u003e\n\u003ctd\u003eList price $465K\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarlier-line (post-2025)\u003c\/td\u003e\n\u003ctd\u003e~120K US\/EU\u003c\/td\u003e\n\u003ctd\u003e+$1.2-1.8B revenue by 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCenters\u003c\/td\u003e\n\u003ctd\u003e150 high-volume\u003c\/td\u003e\n\u003ctd\u003e70% infusions (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eMedicare, NHS, NRDL, private\u003c\/td\u003e\n\u003ctd\u003e$100-$150K\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003eBiopharma\u003c\/td\u003e\n\u003ctd\u003e$50-200M upfront\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA major share of Legend Biotech's cost structure funds discovery and clinical testing of cell therapies-laboratory supplies, researcher salaries, and late‑stage trials that can run tens to hundreds of millions per program (for example, global Phase III oncology trials often exceed $100M). Ongoing R\u0026amp;D spending-Legend reported R\u0026amp;D expense of $338M in 2024-sustains the pipeline needed for future revenue and growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Tech Manufacturing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of Legend Biotech's personalized cell therapies is labor-intensive and uses costly specialized equipment, reagents, and single-dose custom runs that prevent traditional scale economies; industry data shows cell therapy COGS (cost of goods sold) often range $50k-$200k per patient, driven by facility CAPEX, GMP maintenance, and QC testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend must fund a large commercial engine to win in oncology: sales force salaries (US oncology reps avg $160k base + $60k bonus in 2024), medical congress fees (single major meeting booth $250k-$800k), and marketing\/education materials; Legend reported $235m R\u0026amp;D and SG\u0026amp;A share in 2024 with partners covering ~40% of launch promo, leaving significant cash outflow pre-reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and legal costs at Legend Biotech include FDA and EMA filing fees (a new drug application around $3-4M for user fee portions in 2025) plus global patent maintenance (often $1-3M annually) and litigation\/IP defense; overall compliance and legal staffing can run several million per year, typically 5-10% of SG\u0026amp;A for late-stage biotech.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA\/PDUFA user fees ~ $3-4M (2025)\u003c\/li\u003e\n\u003cli\u003eEMA\/PMDA filings \u0026amp; translations $1-2M\u003c\/li\u003e\n\u003cli\u003eGlobal patent portfolio maintenance $1-3M\/year\u003c\/li\u003e\n\u003cli\u003eDedicated compliance\/legal team = several FTEs, 5-10% of SG\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSpecialized transport for Legend Biotech's cryopreserved CAR-T cells costs roughly 3-5x standard pharma shipping, driven by liquid nitrogen containers, real-time IoT tracking, and premium couriers; industry data show per-shipment add-ons of $2,500-$8,000 for high-integrity cold chain services as of 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3-5x cost vs pharma\u003c\/li\u003e\n\u003cli\u003e$2,500-$8,000 per shipment (2025)\u003c\/li\u003e\n\u003cli\u003eCosts cover cryo-containers, real-time tracking, premium couriers\u003c\/li\u003e\n\u003cli\u003eNon-negotiable for product safety and regulatory compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegend's hefty R\u0026amp;D, high cell-therapy COGS, and steep launch \u0026amp; cold‑chain costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegend's costs center on R\u0026amp;D and trials (R\u0026amp;D expense $338M in 2024), high per-patient COGS for cell therapies ($50k-$200k), commercial launch SG\u0026amp;A (US rep comp ~$220k total), regulatory\/legal fees ($3-4M PDUFA + $1-3M patent maintenance) and premium cold-chain shipping ($2,500-$8,000 per shipment).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D expense\u003c\/td\u003e\n\u003ctd\u003e$338M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\/patient\u003c\/td\u003e\n\u003ctd\u003e$50k-$200k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDUFA fee\u003c\/td\u003e\n\u003ctd\u003e$3-4M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent maint.\u003c\/td\u003e\n\u003ctd\u003e$1-3M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain\/shipment\u003c\/td\u003e\n\u003ctd\u003e$2,500-$8,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCarvykti Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCarvykti product sales are Legend Biotech's primary revenue, reflecting its share of net trade sales under the Janssen Biotech partnership; Legend reported $184 million in Carvykti net product revenue recognized in 2025 Q3 year-to-date in territories where it books sales. As Carvykti advances into earlier lines of multiple myeloma, uptake and addressable-market models project revenue growth of several-fold, with peak global sales estimates ranging $3-5 billion annually by the early 2030s.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone Achievement Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegend receives large one-time milestone payments from Janssen tied to clinical, regulatory, and commercial triggers; for example, the 2021 partnership terms included up to $3.5 billion in potential milestones, with Legend already recording multi-hundred‑million dollar receipts that funded R\u0026amp;D and operations in 2022-2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn territories where Janssen leads commercialization, Legend Biotech earns royalties on net sales, creating a steady passive revenue stream that scales with product uptake; for example, Legend reported potential tiered royalties up to mid-teens percent on Teclistamab‑related sales scenarios in 2025 licensing disclosures. Royalties diversify Legend's value capture from its CAR‑T IP, adding recurring cash flow that cushions R\u0026amp;D-driven revenue volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborative research funding: partners often commit to co-fund R\u0026amp;D, cutting Legend Biotech's cash burden and enabling continued CAR-T and cell therapy development; deals in 2024 showed upfront and milestone-backed R\u0026amp;D funding covering 20-40% of program costs, typically tied to milestone deliverables or IND-enabling studies.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces Legend R\u0026amp;D spend 20-40% per program\u003c\/li\u003e\n\u003cli\u003eFunding tied to specific milestones and candidates\u003c\/li\u003e\n\u003cli\u003eOften includes upfront payments plus milestone tranches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Technology Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegend may license proprietary binders and platform tech to other biotechs for non-competing indications, earning upfront fees plus royalties or milestone payments; for example, biopharma licensing deals averaged $20-50M upfront and $100-500M in milestones in 2024.\u003c\/p\u003e\n\u003cp\u003eLicensing converts R\u0026amp;D into cash without commercialization cost, letting Legend monetize research outside its core CAR-T pipeline while retaining strategic assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront fees: immediate cash (typical $20-50M)\u003c\/li\u003e\n\u003cli\u003eMilestones: regulatory\/commercial triggers ($100-500M)\u003c\/li\u003e\n\u003cli\u003eRoyalties: percentage of partner sales (commonly 5-20%)\u003c\/li\u003e\n\u003cli\u003eScope: non-competing indications only\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCarvykti drives $184M YTD; peak $3-5B, deals \u0026amp; royalties fuel multi‑hundredM upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary revenue: Carvykti product sales-$184M YTD through 2025 Q3 in Legend-booked territories; peak global sales projected $3-5B early 2030s. Milestones\/partnering: Janssen deal included up to $3.5B; Legend recorded multi-hundred‑million receipts 2022-24. Royalties\/licensing\/ research funding: tiered royalties mid-teens potential, licensing upfront $20-50M and milestones $100-500M, partners co-fund 20-40% of program costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eKey 2025 figures\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCarvykti sales\u003c\/td\u003e\n\u003ctd\u003e$184M YTD 2025 Q3; $3-5B peak est.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones\u003c\/td\u003e\n\u003ctd\u003eUp to $3.5B deal total; multi‑hundredM received\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing upfront\u003c\/td\u003e\n\u003ctd\u003e$20-50M avg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing milestones\u003c\/td\u003e\n\u003ctd\u003e$100-500M typical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D co‑funding\u003c\/td\u003e\n\u003ctd\u003e20-40% program cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003eUp to mid‑teens %\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354796237131,"sku":"legendbiotech-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/legendbiotech-canvas-business-model.webp?v=1779147700","url":"https:\/\/valuechainanalysis.com\/products\/legendbiotech-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}